Humoral Immune Response to SARS-CoV-2 in Iceland.
Daniel F GudbjartssonGudmundur L NorddahlPall MelstedKristbjorg GunnarsdottirHilma HolmElias EythorssonAsgeir O ArnthorssonDadi HelgasonKristbjorg BjarnadottirRagnar F IngvarssonBrynja ThorsteinsdottirSteinunn KristjansdottirKolbrun BirgisdottirAnna M KristinsdottirMartin I SigurdssonGudny A ArnadottirErna V IvarsdottirMargret AndresdottirFrosti JonssonArna B AgustsdottirJonas BerglundBerglind EiriksdottirRun FridriksdottirElisabet E GardarsdottirMagnus GottfredssonOlafia S GretarsdottirSteinunn GudmundsdottirKjartan R GudmundssonThora R GunnarsdottirArnaldur GylfasonAgnar HelgasonBrynjar O JenssonAslaug JonasdottirHakon JonssonThordur KristjanssonKarl G KristinssonDroplaug N MagnusdottirOlafur T MagnussonLovisa B OlafsdottirSolvi RognvaldssonLouise le RouxGudrun SigmundsdottirAsgeir SigurdssonGardar SveinbjornssonKristin E SveinsdottirManey SveinsdottirEmil A ThorarensenBjarni ThorbjornssonMarianna ThordardottirJona SaemundsdottirS Hjortur KristjanssonKamilla S JosefsdottirGisli MassonGudmundur GeorgssonMar KristjanssonAlma MollerRunolfur PalssonThorolfur GudnasonUnnur ThorsteinsdottirIngileif JonsdottirPatrick SulemKari StefanssonPublished in: The New England journal of medicine (2020)
Our results indicate that antiviral antibodies against SARS-CoV-2 did not decline within 4 months after diagnosis. We estimate that the risk of death from infection was 0.3% and that 44% of persons infected with SARS-CoV-2 in Iceland were not diagnosed by qPCR.